The phase 3 NRG-GU005 trial compared moderately hypofractionated IMRT in 20 to 28 sessions vs SBRT in 5 sessions for efficacy and health-related quality-of-life in men with favorable intermediate-risk ...
For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.
MedPage Today on MSN
SBRT misses the mark in prostate cancer trial
No improvement over intensity-modulated RT in urinary symptoms after 2 years, DFS after 3 ...
Proton therapy reduces radiation to nontargeted tissues, but for men with localized prostate cancer that may not translate to better outcomes, according to early results from the large prospective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results